Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China

Fineline Cube Jun 3, 2026
Company Deals

Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market

Fineline Cube Jun 3, 2026
Company Deals

Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets

Fineline Cube Jun 2, 2026
Company Deals

Simcere Pharmaceutical Secures Exclusive Rights to PrimeGenX’s Pumecitinib Gel for Atopic Dermatitis in Greater China

Fineline Cube Jun 2, 2026
Company Deals

Servier Group Acquires Edgewise Therapeutics’ Muscular Dystrophy Business for Up to $2.65 Billion

Fineline Cube Jun 2, 2026
Policy / Regulatory

China’s NMPA Introduces Comprehensive Medical Device Classification Reforms with 2-5 Year Transitional Periods

Fineline Cube Jun 2, 2026
Company Drug

Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations

Fineline Cube Jun 3, 2026
Company Drug

Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World’s First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule

Fineline Cube Jun 3, 2026
Company Drug

FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration

Fineline Cube Sep 12, 2025

Shanghai‑based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic...

Drug Policy / Regulatory

NMPA Unveils 30‑Working‑Day Pathway to Accelerate Innovative Drug Trials

Fineline Cube Sep 12, 2025

The National Medical Products Administration (NMPA) announced a new regulatory framework—Announcement No. 86 of 2025—that promises to...

Company Drug

Genrix Bio Secures NMPA Approval for GR1803 Bispecific Antibody in Systemic Lupus Erythematosus

Fineline Cube Sep 11, 2025

China‑based Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced that the National Medical Products Administration (NMPA)...

Company Deals

GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58 B

Fineline Cube Sep 11, 2025

China‑based GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) completed a successful initial public offering (IPO) on the...

Company Deals Drug

Remedium Bio Teams Up With Eli Lilly to Push Gene‑Therapy Frontiers for Diabetes and Obesity

Fineline Cube Sep 11, 2025

Remedium Bio, Inc. (Remedium) announced a multi‑target R&D partnership with Eli Lilly & Co. (NYSE: LLY) to...

Company Deals

YolTech Raises 300 Million Yuan Series B, Pushing In‑Vivo Gene‑Editing to the Forefront

Fineline Cube Sep 11, 2025

The AstraZeneca‑CICC Medical Industry Fund announced that it led a Series B financing round for China‑based...

Company Drug

Novartis Secures Tabrecta Approval in China for METex14 NSCLC

Fineline Cube Sep 11, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its MET‑receptor tyrosine kinase inhibitor Tabrecta (capmatinib...

Company Drug Policy / Regulatory

China to Add HPV Vaccine to National Immunization Program, Pledges Free Shots for Eligible Girls

Fineline Cube Sep 11, 2025

At a State Council Information Office press conference, Deputy Director of the National Health Commission...

Policy / Regulatory

China’s Drug Evaluation Authority Issues Draft Rules for Class I ATMP Meetings

Fineline Cube Sep 11, 2025

The Center for Drug Evaluation (CDE), part of China’s National Medical Products Administration (NMPA), published...

Policy / Regulatory

China Unveils “Healthcare Foundation Strengthening Plan” to Bring Clinics Within 15‑Minute Reach

Fineline Cube Sep 11, 2025

The State Council released the Implementation Plan for the Healthcare Foundation Strengthening Project, setting a...

Company Drug

TransThera Sciences Secures China Phase II Trial Approval for Tinengotinib‑Fulvestrant Combination

Fineline Cube Sep 11, 2025

TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced that the China National Medical Products Administration has...

Company Deals

Innovent Biologics & Cowell Health Forge Strategic Alliance to Boost Drug Access

Fineline Cube Sep 11, 2025

Innovent Biologics Inc. (HKG: 1801) announced a strategic cooperation agreement with Cowell Health. The partnership is...

Company Drug

Taiji Group Secures NMPA Approval to Begin Clinical Trials of Semaglutide Biosimilar

Fineline Cube Sep 11, 2025

China‑based Chongqing Taiji Industry (Group) Co., Ltd. (Taiji Group, SHA: 600129) announced that its semaglutide...

Company Drug

Betta Pharmaceuticals Secures NMPA Approval for MCLA‑129/Ensartinib Combination in Advanced Solid Tumors

Fineline Cube Sep 11, 2025

China-based Betta Pharmaceuticals (SHE: 300558) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Deals

Qilu Pharmaceutical & FDSTC Announce Strategic Partnership to Boost China’s Biomedical Innovation

Fineline Cube Sep 10, 2025

China‑based Qilu Pharmaceutical and the Foundation for the Development of Science and Technology in China (FDSTC),...

Company Deals

Corxel and WuXi Forge Cardiovascular Partnership to Accelerate Drug Development

Fineline Cube Sep 10, 2025

China‑based Corxel Pharmaceuticals (CORXEL) and WuXi STA, a subsidiary of WuXi AppTec (SHA: 603259), have...

Company Deals Medical Device

Danaher Partners with Beckman to Advance Alzheimer’s Blood‑Biomarker Diagnosis

Fineline Cube Sep 10, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced that its operating subsidiary,...

Company Drug Medical Device

Johnson & Johnson Secures FDA Approval for INLEXZO, a Ground‑breaking Intravesical System for Bladder Cancer

Fineline Cube Sep 10, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug...

Others

China’s 11th National Drug VBP Draft Unveils Major Pricing & Competition Reforms

Fineline Cube Sep 10, 2025

The second‑draft rules for China’s 11th round of national centralized drug procurement (VBP 11th) have...

Company Deals Drug

Kexing Biopharm Secures Global Rights to Humanwell PuraCap’s Nintedanib

Fineline Cube Sep 10, 2025

China‑listed Kexing Biopharm Co., Ltd. (SHA: 688136) announced today a strategic commercialization agreement with Humanwell...

Posts pagination

1 … 115 116 117 … 677

Recent updates

  • Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China
  • Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations
  • Genesis MedTech Secures CE Mark for World’s First Integrated Scissor-Type Ultrasonic Scalpel, Following 2025 China Approval
  • Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market
  • Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World’s First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China

Company Drug

Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations

Company Medical Device

Genesis MedTech Secures CE Mark for World’s First Integrated Scissor-Type Ultrasonic Scalpel, Following 2025 China Approval

Company Deals

Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.